Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
The current Medicare operation—reimbursing medical goods and services to a growing number of people without basing the reimbursement benefit on the actual cost of the services—is unsustainable, but there are some possible remedies.
Physicians have an obligation to consider a patient’s quality of life when making treatment decisions and should consider giving patients the options of withholding or withdrawing aggressive treatment if that treatment will not restore the kind of life the patient finds meaningful.
A physician defends her position that children should only participate in clinical trials when they have child assent and the parents also have been educated about the purpose of the research when there is no direct benefit to the child.
Two physicians offer commentaries about the use of prenatal predictive testing for a late-onset disease like Huntington's and question whether the pregnant woman should ultimately have the decisional autonomy to determine the quality of life of the unborn child.
Two physicians offer commentaries about the use of prenatal predictive testing for a late-onset disease like Huntington's and question whether the pregnant woman should ultimately have the decisional autonomy to determine the quality of life of the unborn child.
Physicians should seriously weigh the benefits and risks involved prior to discussing the possibility of genetic testing with a patient or referring them to a genetic counselor.